Anne Beaufour - Ipsen SA Director

IPN Stock  EUR 109.40  0.10  0.09%   

Director

Ms. Anne Beaufour was Director of Ipsen SA since August 30, 2005 and is also Chairman of the Company Appointments and Governance Committee and Member of the Strategic Committee. She works as Vice Chairman of the Board and Deputy Director of Mayroy, Director and Chairman of the Board of Beech Tree SA, Manager of Highrock S.a.r.l. and Manager of Bluehill Participations S.a.r.l since 2020.
Age 55
Tenure 4 years
Phone33 1 58 33 50 00
Webhttps://www.ipsen.com
Beaufour held several other posts, including Manager of SCI du 47, FinHestia, HenriHeine, SCI Deux Chateaudun and SCI de la Fraternite, among others. She holds a Bachelors degree in Geology from Universite de Paris.

Ipsen SA Management Efficiency

The company has return on total asset (ROA) of 0.1026 % which means that it generated a profit of $0.1026 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1944 %, meaning that it generated $0.1944 on every $100 dollars invested by stockholders. Ipsen SA's management efficiency ratios could be used to measure how well Ipsen SA manages its routine affairs as well as how well it operates its assets and liabilities.
Ipsen SA has accumulated 667 M in total debt with debt to equity ratio (D/E) of 0.45, which is about average as compared to similar companies. Ipsen SA has a current ratio of 1.55, which is within standard range for the sector. Debt can assist Ipsen SA until it has trouble settling it off, either with new capital or with free cash flow. So, Ipsen SA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Ipsen SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Ipsen to invest in growth at high rates of return. When we think about Ipsen SA's use of debt, we should always consider it together with cash and equity.
Ipsen S.A. operates as a biopharmaceutical company worldwide. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. IPSEN operates under Drug ManufacturersSpecialty Generic classification in France and is traded on Paris Stock Exchange. It employs 5700 people. Ipsen SA (IPN) is traded on Euronext Paris in France and employs 5,000 people.

Management Performance

Ipsen SA Leadership Team

Elected by the shareholders, the Ipsen SA's board of directors comprises two types of representatives: Ipsen SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ipsen. The board's role is to monitor Ipsen SA's management team and ensure that shareholders' interests are well served. Ipsen SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ipsen SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Marc Garidel, Chairman, CEO and Chairman of Strategic Committee
Paul Sekhri, Independent Director
Henri Beaufour, Director
Gwenan White, Executive Vice President Communications and Public Affairs
Francois Garnier, Executive Vice President General Counsel, Member of the Executive Committee
Carol Xueref, Independent Director
Richard Paulson, Executive Vice President and Chief Executive Officer of Ipsen North America
Dominique Bery, Executive Vice President, Strategy and Transformation
Yan Moore, Senior Vice President Head of Oncology Therapeutics Area
Aidan Murphy, Executive Vice-President Technical Operations
Piet Wigerinck, Independent Director
David Loew, Chief Executive Officer, Director
Margaret Liu, Independent Director
Craig Marks, VicePres Relations
Howard Mayer, Executive Vice President, Head of Research & Development
Yan MD, VP Area
Regis Mulot, Chief Human Resource Officer, Executive Vice President
Alexander McEwan, Vice President and Head of Radiopharmaceuticals
Ivana MagovcevicLiebisch, Executive Vice President Chief Business Officer
Philippe Bonhomme, Director, Permanent representative of Beech Tree SA
Michele Ollier, Independent Director
Carol Stuckley, Independent Director
JeanMarc Parant, Director, representing Employees
Steven Hildemann, Executive Vice President Chief Medical Officer, Head of Global Medical Affairs and Pharmacovigilance
Harout Semerjian, Executive Vice President & President Specialty Care International & Global Franchises
Anne Beaufour, Director, Permanent representative of Highrock S.àr.l.
Philippe LopesFernandes, Executive Vice President Chief Business Officer
Aymeric Chatelier, Interim Chief Executive Officer, Chief Financial Officer, Executive Vice President
Benoit Hennion, Executive Vice President and President Consumer Helathcare
Dominique Laymand, Executive Vice President, Chief Ethics and Compliance Officer
Antoine Flochel, Vice Chairman of the Board
Stephan Gagne, Head Office

Ipsen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ipsen SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Ipsen Stock

Ipsen SA financial ratios help investors to determine whether Ipsen Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ipsen with respect to the benefits of owning Ipsen SA security.